Want to see SANA full AI Analyst Report?
SANA Stock Chart & Stats
$3.52
$3.38(204.85%)
At close: 4:00 PM EST
$3.52
$3.38(204.85%)
Day’s Range― - ―
52-Week Range$2.61 - $6.55
Previous CloseN/A
Volume118.31M
Average Volume (3M)3.17M
Market Cap
$1.13B
Enterprise Value$940.93
Total Cash (Recent Filing)$160.49M
Total Debt (Recent Filing)$73.74M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Nov 05, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding299,360,630
10 Day Avg. Volume2,348,486
30 Day Avg. Volume3,172,381
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)6.41
Price to Sales (P/S)0.00
P/FCF Ratio-7.12
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.00Price Target Upside127.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.65
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Progressing Programs Into ClinicAdvancing SC451 and SG293 toward initial clinical studies marks a structural de-risking step for a development-stage biotech. Clinical starts create durable operational milestones, enable translational validation, and can trigger partnerships or milestone payments over the next 2–6 months and beyond.
Near-term Cash Runway Into Mid-2027A reported cash balance of $160.5M with runway into mid-2027 materially extends the company's ability to fund clinical initiations and development activities without immediate capital raises. This reduces near-term liquidity pressure and gives time to reach value-driving milestones.
Proven Access To Capital MarketsA recent $69M equity raise demonstrates continuing access to public capital, a vital structural capability for a pre-revenue biotech. Reliable financing channels support sustained R&D spend and trial execution, enabling the company to advance programs while pursuing partnerships or milestones.
Bears Say
No Meaningful Product RevenueThe absence of recurring product revenue leaves the company dependent on financing and partnerships to fund operations. Persistent net losses (~-$212M TTM) mean long-term sustainability hinges on clinical success or outsized collaborations rather than internal cash generation.
Consistent Negative Operating Cash FlowContinued negative operating and free cash flow requires ongoing external capital to sustain R&D and trials. Although burn has improved, the structural reliance on financing increases dilution and execution risk until the company can generate durable revenue or secure milestone-backed partnerships.
Balance Sheet Erosion And Negative ROEA sharp decline in shareholders' equity and sustained negative ROE reflect accumulated losses and value erosion, weakening financial flexibility. Diminished equity cushions limit borrowing or strategic maneuvering and heighten sensitivity to execution setbacks or larger-than-expected cash needs.
Sana Biotechnology News
SANA FAQ
What was Sana Biotechnology, Inc.’s price range in the past 12 months?
Sana Biotechnology, Inc. lowest stock price was $2.61 and its highest was $6.55 in the past 12 months.
What is Sana Biotechnology, Inc.’s market cap?
Sana Biotechnology, Inc.’s market cap is $1.13B.
When is Sana Biotechnology, Inc.’s upcoming earnings report date?
Sana Biotechnology, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 82 days.
How were Sana Biotechnology, Inc.’s earnings last quarter?
Sana Biotechnology, Inc. released its earnings results on Aug 10, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.147 by -$0.073.
Is Sana Biotechnology, Inc. overvalued?
According to Wall Street analysts Sana Biotechnology, Inc.’s price is currently Undervalued.
Does Sana Biotechnology, Inc. pay dividends?
Sana Biotechnology, Inc. does not currently pay dividends.
What is Sana Biotechnology, Inc.’s EPS estimate?
Sana Biotechnology, Inc.’s EPS estimate is -0.15.
How many shares outstanding does Sana Biotechnology, Inc. have?
Sana Biotechnology, Inc. has 299,360,630 shares outstanding.
What happened to Sana Biotechnology, Inc.’s price movement after its last earnings report?
Sana Biotechnology, Inc. reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.147. Following the earnings report the stock price went up 4.986%.
Which hedge fund is a major shareholder of Sana Biotechnology, Inc.?
Currently, no hedge funds are holding shares in SANA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sana Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (127.27% Upside)
$8.00 (127.27% Upside)
Blogger Sentiment
Neutral
SANA Sentiment 50%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 2.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.32%
Trailing 12-Months
Company Description
Sana Biotechnology, Inc.
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
SANA Stock 12 Month Forecast
Average Price Target
$8.00
▲(127.27% Upside)
Technical Analysis
Geron
―
Editas Medicine
―
Crispr Therapeutics AG
―
Taysha Gene Therapies
―
Prime Medicine, Inc.
―
Ownership Overview
13.58% Insiders
10.91% Mutual Funds
1.60% Other Institutional Investors
64.05% Public Companies and
Individual Investors